Epidermal growth factor receptor (EGFR)-mutant lung cancer is known to have an immune-deprived microenvironment characterized by a low tumor mutation burden, increased immunosuppressive cytokines, and increased regulatory T (Treg)-cell infiltration [1,2]. The gene discussed is EGFR; the disease is lung cancer.